Search Results - "Saxena, Parmita"

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin by GARNER, Andrew P, BIALUCHA, Carl U, YAN CHEN, HUIQIN WANG, JINSHENG LIANG, DAS, Rita, MOSHER, Rebecca, JIAN GU, HUANG, Alan, HAUBST, Nicole, ZEHETMEIER, Carolin, HABERL, Manuela, SPRAGUE, Elizabeth R, ELIS, Winfried, KUNZ, Christian, HEIDT, Analeah B, HERLIHY, Kara, MURTIE, Joshua, SCHULLER, Alwin, ARTEAGA, Carlos L, SELLERS, William R, ETTENBERG, Seth A, GARRETT, Joan T, QING SHENG, SHARON LI, SINESHCHEKOVA, Olga, SAXENA, Parmita, SUTTON, Cammie R, DONGSHU CHEN

“…HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in cancer leads to HER3-mediated oncogenic activation of phosphoinositide…”
Get full text

Integrin alphaVbeta1 inhibition ameliorates liver fibrosis in mice by Chen, Richard, Saxena, Parmita, Senices, Mayra, Yadav, Vinod, Harrison, Bryce, Dowling, James E., Nowakowski, Patrycja, Cappellucci, Laura, Finley, Faith, Sullivan, Andrew, Kennedy-Curran, Angela, Moy, Terence, Lin, Albert, Cui, Dan, Ray, Adrian, Lippa, Blaise, Lugovskoy, Alex, Rogers, Bruce, Wang, Liangsu, Lu, Min

Get full text

FRI247 - Integrin alphaVbeta1 inhibition ameliorates liver fibrosis in mice by Chen, Richard, Saxena, Parmita, Senices, Mayra, Yadav, Vinod, Harrison, Bryce, Dowling, James E., Nowakowski, Patrycja, Cappellucci, Laura, Finley, Faith, Sullivan, Andrew, Kennedy-Curran, Angela, Moy, Terence, Lin, Albert, Cui, Dan, Ray, Adrian, Lippa, Blaise, Lugovskoy, Alex, Rogers, Bruce, Wang, Liangsu, Lu, Min

Get full text

Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers by Bialucha, Carl U, Collins, Scott D, Li, Xiao, Saxena, Parmita, Zhang, Xiamei, Dürr, Clemens, Lafont, Bruno, Prieur, Pierric, Shim, Yeonju, Mosher, Rebecca, Lee, David, Ostrom, Lance, Hu, Tiancen, Bilic, Sanela, Rajlic, Ivana Liric, Capka, Vladimir, Jiang, Wei, Wagner, Joel P, Elliott, GiNell, Veloso, Artur, Piel, Jessica C, Flaherty, Meghan M, Mansfield, Keith G, Meseck, Emily K, Rubic-Schneider, Tina, London, Anne Serdakowski, Tschantz, William R, Kurz, Markus, Nguyen, Duc, Bourret, Aaron, Meyer, Matthew J, Faris, Jason E, Janatpour, Mary J, Chan, Vivien W, Yoder, Nicholas C, Catcott, Kalli C, McShea, Molly A, Sun, Xiuxia, Gao, Hui, Williams, Juliet, Hofmann, Francesco, Engelman, Jeffrey A, Ettenberg, Seth A, Sellers, William R, Lees, Emma

“…Despite an improving therapeutic landscape, significant challenges remain in treating the majority of patients with advanced ovarian or renal cancer. We…”
Get more information

Abstract 2974: Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer by Collins, Scott D., Saxena, Parmita, Li, Xiao Y., Shim, Yeonju, Ostrom, Lance, Yoder, Nicholas C., Catcott, Kalli C., McShea, Molly A., Sun, Xiuxia, Bilic, Sanela, Tschantz, William R., Flaherty, Meghan, Mansfield, Keith, Hu, Tiancen, Capka, Vladimir, Kurz, Markus, Liric Rajlic, Ivana, Serdakowski London, Anne, Nguyen, Duc, Mosher, Rebecca, Meyer, Matthew J., Bourret, Aaron, Saeh, Jamal, Cameron, Scott, Lees, Emma, Bialucha, Carl U.

“…Abstract In an attempt to mine tumor versus normal mRNA expression datasets for novel tumor antigens, we identified the Cadherin-6 (CDH6) gene as frequently…”
Get full text

PSA regulates androgen receptor expression in prostate cancer cells by Saxena, Parmita, Trerotola, Marco, Wang, Tao, Li, Jing, Sayeed, Aejaz, VanOudenhove, Jennifer, Adams, Dave S., FitzGerald, Thomas J., Altieri, Dario C., Languino, Lucia R.

“…BACKGROUND Prostate‐specific antigen (PSA) is a pivotal downstream target gene of the androgen receptor (AR), and a serum biomarker to monitor prostate cancer…”
Get full text

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates by Catcott, Kalli C, McShea, Molly A, Bialucha, Carl Uli, Miller, Kathy L, Hicks, Stuart W, Saxena, Parmita, Gesner, Thomas G, Woldegiorgis, Mikias, Lewis, Megan E, Bai, Chen, Fleming, Michael S, Ettenberg, Seth A, Erickson, Hans K, Yoder, Nicholas C

“…Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by…”
Get full text

Abstract 5442: Microscale methods for preparation and screening of antibody-drug conjugates by Yoder, Nicholas C., Catcott, Kalli C., McShea, Molly A., Bialucha, Carl Uli, Saxena, Parmita, Bai, Chen, Miller, Kathy L., Gesner, Thomas G., Woldegiorgis, Mikias, Hicks, Stuart W., Lewis, Megan E., Fleming, Michael S., Erickson, Hans K., Ettenberg, Seth E., Keating, Thomas A.

“…Abstract Antibody-drug conjugates (ADCs) are hybrid biotherapeutics that combine the targeting specificity of monoclonal antibodies with chemically conjugated,…”
Get full text

Abstract LB-201: Nuclear localization of Src, androgen receptor and PSA in prostate cancer by Saxena, Parmita, Wang, Tao, Adams, Dave S., Gioeli, Daniel, FitzGerald, Thomas J., Languino, Lucia R.

“…Abstract Src signaling plays an important role in prostate cancer (PrCa) progression. Dasatinib, an oral src family kinase inhibitor, is being tested in…”
Get full text

Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation by Garner, Andrew, Sheng, Qing, Bialucha, Uli, Chen, Dongshu, Chen, Yan, Das, Rita, Elis, Winfried, Heidt, Analeah, Kunz, Christian, Li, Sharon, Liang, Jinsheng, Murtie, Joshua, Saxena, Parmita, Schuller, Alwin, Sineshchekova, Olga, Sprague, Elizabeth, Wang, Hui Qin, Huang, Alan, Ettenberg, Seth

“…Abstract HER3 (ErbB3) is a member of the ErbB family of receptor tyrosine kinases (RTK). Inappropriate HER2/ HER3 dimerization as a result of HER2 or…”
Get full text

Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates by Catcott, Kalli C., McShea, Molly A., Bialucha, Carl Uli, Miller, Kathy L., Hicks, Stuart W., Saxena, Parmita, Gesner, Thomas G., Woldegiorgis, Mikias, Lewis, Megan E., Bai, Chen, Fleming, Michael S., Ettenberg, Seth A., Erickson, Hans K., Yoder, Nicholas C.

“…Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by…”
Get full text